Mark E. Bunnage
EVP, Chief Scientific Officer · VERTEX PHARMACEUTICALS INC / MA
- 2026
- May 19, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Mark E. Bunnage files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Jeffrey M. Leiden - $60.94M in VRTX purchases and sales in the last 12 months
- Amit Sachdev - $28.38M in VRTX purchases and sales in the last 12 months
- Reshma Kewalramani - $19.74M in VRTX purchases and sales in the last 12 months
- Carmen Bozic - $11.31M in VRTX purchases and sales in the last 12 months
- Charles F. Wagner Jr. - $6.38M in VRTX purchases and sales in the last 12 months
- Duncan McKechnie - $5.66M in VRTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Mark E. Bunnage?
Mark E. Bunnage is a corporate insider, tracked as EVP, Chief Scientific Officer of VERTEX PHARMACEUTICALS INC / MA (VRTX). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Mark E. Bunnage last file a Form 4?
The most recent primary Form 4 on record is dated 19 May 2026, one of 5 filings going back to 2026.
Has Mark E. Bunnage been buying or selling stock?
Recorded transactions: 0 open-market purchases and 5 open-market sales ($3.00M) across all tracked filings.
